Investigational Drug Details
| Drug ID: | D069 |
| Drug Name: | CF102 |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB12885 |
| DrugBank Description: | CF-102 has been used in trials studying the treatment of Chronic Hepatitis C and Hepatocellular Carcinoma. |
| PubChem ID: | 3035850 |
| CasNo: | 163042-96-4 |
| Repositioning for NAFLD: | No |
| SMILES: | O[C@H]1[C@H](n2c3c(nc2)c(NCc2cc(I)ccc2)nc(n3)Cl)O[C@@H]([C@H]1O)C(=O)NC |
| Structure: |
|
| InChiKey: | IPSYPUKKXMNCNQ-PFHKOEEOSA-N |
| Molecular Weight: | 544.737 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | ADORA3 receptor antagonist activity |
| Therapeutic Category: | Anticancer agent |
| Clinical Trial Progress: | Phase 2 completed (NCT02927314: A3AR is a valid target; namodenoson 25 mg b.d. was safe and demonstrated efficacy signals.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0105 | NCT02927314 | Phase 2 | Completed | No Results Available | November 27, 2017 | March 17, 2020 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|